Tue Jun 24 12:20:00 UTC 2025: Okay, here’s a summary of the provided text followed by a rewritten version as a news article.

**Summary:**

Nektar Therapeutics has announced positive Phase 2b trial results for their investigational drug rezpegaldesleukin in treating moderate-to-severe atopic dermatitis (eczema). The study (REZOLVE-AD) met its primary endpoint, showing significant improvement in eczema severity scores compared to a placebo. It also met key secondary endpoints, including reduced itch and visible skin improvement. The drug showed a rapid onset of action and a good safety profile. Nektar is also developing rezpegaldesleukin for alopecia areata (hair loss), with top-line data expected later this year. A conference call with management and experts will discuss the findings.

**News Article:**

**Nektar Therapeutics Announces Positive Phase 2b Results for Atopic Dermatitis Drug**

**SAN FRANCISCO, CA – June 24, 2025** – Nektar Therapeutics (Nasdaq: NKTR) today announced positive results from its Phase 2b REZOLVE-AD study, evaluating rezpegaldesleukin as a treatment for moderate-to-severe atopic dermatitis (eczema). The study, involving 393 patients, demonstrated statistically significant improvements in eczema severity scores compared to a placebo.

Rezpegaldesleukin, a novel IL-pathway agonist and regulatory T-cell proliferator, met its primary endpoint of mean improvement in the Eczema Area and Severity Score (EASI) at week 16. Key secondary endpoints were also achieved, including significant reductions in itch (Itch NRS) and visible skin improvement (EASI-75, EASI-90, vIGA-AD).

“These results present a new therapeutic hypothesis for treatment of dermatological diseases,” said Prof. David Rosmarin M.D., Chair, Department of Dermatology and Associate Professor of Dermatology, Indiana University School of Medicine.

The study also showed a rapid onset of action and a favorable safety profile, with the most common side effect being mild-to-moderate injection site reactions. Importantly, there was no increased risk of conjunctivitis, oral ulcers, or infections observed in the trial.

“We believe that the REZOLVE-AD study results clearly demonstrate that Nektar has established a new biology and harnessed the promise of Tregs as an important potential therapeutic modality to treat inflammatory skin disorders,” said Howard W. Robin, President and CEO of Nektar Therapeutics.

Nektar Therapeutics is also investigating rezpegaldesleukin for the treatment of alopecia areata, with top-line Phase 2b data expected in the fourth quarter of 2025.

A conference call and webcast with management and atopic dermatitis experts will be held today at 8:15 am ET to discuss the findings in more detail.

Read More